Literature DB >> 35061101

Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial.

Archana Rai1,2, Kim A Connelly2,3,4, Subodh Verma2,3,4,5, C David Mazer2,4,6, Hwee Teoh4,5,7, Ming-Yen Ng8, Idan Roifman2,9, Adrian Quan4,5, Marina Pourafkari1,10, Laura Jimenez-Juan1,2, Venkat Ramanan9, Yin Ge2,3, Djeven P Deva11,12, Andrew T Yan13,14,15,16.   

Abstract

Entities:  

Keywords:  Diabetes; Empagliflozin; LV diastolic function; SGLT2 inhibitors

Mesh：

Substances：

Year:  2022        PMID： 35061101     DOI： 10.1007/s00592-021-01823-6

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN： 0940-5429            Impact factor:   4.280


× No keyword cloud information.
  7 in total

1.  Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial.

Authors:  Karan Bami; Sumeet Gandhi; Howard Leong-Poi; Andrew T Yan; Edwin Ho; Mohammed Zahrani; Vinay Garg; Fei Zuo; Hwee Teoh; Adrian Quan; Lawrence A Leiter; Richard E Gilbert; Bernard Zinman; Kevin E Thorpe; Peter Jüni; C David Mazer; Subodh Verma; Geraldine Ong; Kim A Connelly
Journal:  J Am Soc Echocardiogr       Date:  2020-03-18       Impact factor: 5.251

2.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

3.  Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.

Authors:  Subodh Verma; C David Mazer; Andrew T Yan; Tamique Mason; Vinay Garg; Hwee Teoh; Fei Zuo; Adrian Quan; Michael E Farkouh; David H Fitchett; Shaun G Goodman; Ronald M Goldenberg; Mohammed Al-Omran; Richard E Gilbert; Deepak L Bhatt; Lawrence A Leiter; Peter Jüni; Bernard Zinman; Kim A Connelly
Journal:  Circulation       Date:  2019-08-22       Impact factor: 29.690

4.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

Authors:  Stefan D Anker; Javed Butler; Gerasimos Filippatos; João P Ferreira; Edimar Bocchi; Michael Böhm; Hans-Peter Brunner-La Rocca; Dong-Ju Choi; Vijay Chopra; Eduardo Chuquiure-Valenzuela; Nadia Giannetti; Juan Esteban Gomez-Mesa; Stefan Janssens; James L Januzzi; Jose R Gonzalez-Juanatey; Bela Merkely; Stephen J Nicholls; Sergio V Perrone; Ileana L Piña; Piotr Ponikowski; Michele Senni; David Sim; Jindrich Spinar; Iain Squire; Stefano Taddei; Hiroyuki Tsutsui; Subodh Verma; Dragos Vinereanu; Jian Zhang; Peter Carson; Carolyn Su Ping Lam; Nikolaus Marx; Cordula Zeller; Naveed Sattar; Waheed Jamal; Sven Schnaidt; Janet M Schnee; Martina Brueckmann; Stuart J Pocock; Faiez Zannad; Milton Packer
Journal:  N Engl J Med       Date:  2021-08-27       Impact factor: 176.079

5.  Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.

Authors:  James L Januzzi; Jialin Xu; JingWei Li; Wayne Shaw; Richard Oh; Michael Pfeifer; Javed Butler; Naveed Sattar; Kenneth W Mahaffey; Bruce Neal; Michael K Hansen
Journal:  J Am Coll Cardiol       Date:  2020-11-03       Impact factor: 24.094

6.  Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus: The IDDIA Trial.

Authors:  Chi Young Shim; Jiwon Seo; Iksung Cho; Chan Joo Lee; In-Jeong Cho; Purevjargal Lhagvasuren; Seok-Min Kang; Jong-Won Ha; Gyoonhee Han; Yangsoo Jang; Geu-Ru Hong
Journal:  Circulation       Date:  2020-11-13       Impact factor: 29.690

7.  Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.

Authors:  Matthias Rau; Kirsten Thiele; Niels-Ulrik Korbinian Hartmann; Alexander Schuh; Ertunc Altiok; Julia Möllmann; András P Keszei; Michael Böhm; Nikolaus Marx; Michael Lehrke
Journal:  Cardiovasc Diabetol       Date:  2021-01-07       Impact factor: 9.951
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.